Logos Global Management’s Rocket Pharmaceuticals RCKT Stock Holding History

Logos Global Management’s Portfolio RCKT Stock Details RCKT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-325,000	Closed	-$6M	–	66
2024 Q3	$6M	Sell	325,000 -25,000	-7%	-$512K	0.65%	35
2024 Q2	$7.54M	Sell	350,000 -950,000	-73%	-$21.8M	0.61%	40
2024 Q1	$35M	Buy	1,300,000 +25,000	+2%	+$710K	2.83%	11
2023 Q4	$38.2M	Sell	1,275,000 -700,000	-35%	-$15.4M	3.57%	10
2023 Q3	$40.5M	Buy	1,975,000 +1,725,000	+690%	+$31.4M	5.4%	4
2023 Q2	$4.97M	Sell	250,000 -650,000	-72%	-$13.1M	0.68%	41
2023 Q1	$15.4M	Buy	900,000 +150,000	+20%	+$2.94M	2.21%	18
2022 Q4	$14.7M	Buy	+750,000	New	+$13.8M	1.72%	21
2020 Q3	–	Sell	-150,000	Closed	-$3.14M	–	57
2020 Q2	$3.14M	Buy	150,000 +134,191	+849%	+$2.42M	0.63%	37
2020 Q1	$221K	Sell	15,809 -207,528	-93%	-$4.11M	0.08%	41
2019 Q4	$5.08M	Buy	+223,337	New	+$3.73M	1.25%	23

Other funds holding RCKT

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Logos Global Management's RCKT Position: Q4 2024 in Review

Logos Global Management sold out of Rocket Pharmaceuticals (RCKT) in Q4 2024, closing a stake of 325,000 shares — an estimated $6M sold.

Logos Global Management first reported a position in RCKT in Q4 2019 and held it in 11 quarters. The position peaked at $40.5M in Q3 2023. 225 funds tracked by Wall St. Rank hold RCKT as of Q4 2024.

Logos Global Management reported no remaining Rocket Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
Logos Global Management sold 325,000 Rocket Pharmaceuticals shares in Q4 2024, an estimated $6M.
Logos Global Management first reported a position in Rocket Pharmaceuticals in Q4 2019 and held it in 11 quarters.
Logos Global Management's Rocket Pharmaceuticals position peaked at $40.5M in Q3 2023.
225 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q4 2024.

Based on Logos Global Management's 13F filing for Q4 2024, filed 14 Feb 2025.